Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.73 |
| ▸ | RAB9A | P51151 | 5/20 | 0.73 |
| ▸ | POLB | P06746 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | SMO | Q99835 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32664390 | 1.00 | CASP3 (1.00) | CASP3SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL980108 | 0.92 | CASP3 (0.86) | CASP3SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL978553 | 0.89 | CASP3 (0.81) | CASP3SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL980586 | 0.89 | CASP3 (0.80) | CASP3SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL29350605 | 0.89 | SMN1; SMN2 (0.80) | CASP3SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL18216694 | 0.89 | SMN1; SMN2 (0.80) | CASP3SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL980173 | 0.87 | SMN1; SMN2 (0.77) | CASP3SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL982575 | 0.85 | SMN1; SMN2 (1.00) | CASP3SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL980106 | 0.84 | RAB9A (0.78) | CASP3SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL979433 | 0.79 | SMN1; SMN2 (0.82) | CASP3SMN1; SMN2RAB9APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9592229-B2 | Potent anticancer activity via dual compound activation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2819661-B1 | POTENT ANTICANCER ACTIVITY VIA DUAL COMPOUND ACTIVATION | UNIV ILLINOIS (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20150099759-A1 | POTENT ANTICANCER ACTIVITY VIA DUAL COMPOUND ACTIVATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-04-09 | — | — | US | disclosed |
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099759-A1 | POTENT ANTICANCER ACTIVITY VIA DUAL COMPOUND ACTIVATION | BAD, MCL1, BAX | CASP3 5/4885SMN1; SMN2 1287/4885RAB9A 1358/4885 |
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | CASP7, CASP3, CASP6 | CASP3 2/4885SMN1; SMN2 1555/4885RAB9A 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.